Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return

Simply Wall St.03-01

Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616584932?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-01 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616584932","market":"nz","top_or_hot":-1,"title":"Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return","media":"Simply Wall St.","content":"<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-stro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 04:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-stro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-stro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-stro","article_id":"2616584932","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-stro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616584932","pubTimestamp":1772310532,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny of its valuation.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite a recent 7 day share price return of 7.2% decline and some short term volatility, Shanghai Henlius Biotech’s 1 year total shareholder return of 144.26% and very large 3 year total shareholder return suggest momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","TSS":"Total System Services","02696":"复宏汉霖"},"translate_title":"上海复宏汉霖生物科技（SEHK：2696）在强劲的一年股东总回报后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02696":0.9,"TSS":1.5,"LABU":1.5},"content_text":"Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny of its valuation. See our latest analysis for Shanghai Henlius Biotech. Despite a recent 7 day share price return of 7.2% decline and some short term volatility, Shanghai Henlius Biotech’s 1 year total shareholder return of 144.26% and very large 3 year total shareholder return suggest momentum has been strong over a longer horizon. If this kind of move in a biotech name has your attention, it could be a good moment to broaden your search and check out 113 healthcare AI stocks identified by our screener. With Shanghai Henlius Biotech trading at HK$67.05 and sitting at a sizeable discount to a HK$109.70 price target and intrinsic value estimates, you have to ask: is this a genuine opportunity, or is the market already baking in future growth? AdvertisementPrice-to-Earnings of 38.8x: Is it justified? Shanghai Henlius Biotech closed at HK$67.05, and the current P/E of 38.8x puts a clear focus on what the market is willing to pay for its earnings today. The P/E ratio compares the share price to earnings per share. A higher figure often signals that investors are paying up for expected future profits, especially in sectors like biotech where product pipelines and clinical progress can be key drivers. For Shanghai Henlius Biotech, this means the current market price reflects expectations about how its oncology and autoimmune portfolio might translate into future earnings. Compared with the Asian biotechs industry average P/E of 41.2x, Shanghai Henlius Biotech sits at a lower multiple. This suggests investors are paying less for each unit of earnings than they are for the broader regional peer group. At the same time, the SWS fair P/E estimate of 20.5x is much lower than the current 38.8x. This gap highlights how far the market could move if pricing ever aligned with that fair ratio benchmark. Explore the SWS fair ratio for Shanghai Henlius Biotech Result: Price-to-Earnings of 38.8x (OVERVALUED) However, you still have to weigh risks such as clinical or regulatory setbacks in its broad pipeline and the possibility that high expectations around the 38.8x P/E ease off. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another View: DCF Points to Deep Undervaluation While the 38.8x P/E hints at a rich price tag, our DCF model presents a different view, with a fair value estimate of HK$182.52 per share versus the current HK$67.05. That 63.3% discount raises a simple question: is sentiment too cautious here? Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 220 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals leaves you unsure, this may be a good time to review the full picture yourself and weigh both sides carefully. You can start with 4 key rewards and 1 important warning sign. Looking for more investment ideas? If this stock has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted ideas that could suit different investing goals.  Spot potential mispricing by checking out our 220 high quality undervalued stocks, built to highlight companies where price and fundamentals may not fully line up. Strengthen your income focus by scanning 445 dividend fortresses, featuring companies with yields above 5% that might appeal if you prioritise regular cash returns. Lean toward resilience by reviewing our 324 resilient stocks with low risk scores, which filters for businesses with lower risk scores that may offer a calmer ride through volatility.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616584932","isCrawlerRequest":true}